Rein Therapeutics Inc.

RNTX

Overview and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI 01 for …

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$57M

EPS-$1.72

P/E-0.38

P/FCF-3.02

EV/EBITDA-0.33

FCF Yield–

Div. Yield–

Net Debt/FCF2.2x

Rein Therapeutics Inc. intrinsic value

52-Week Range

$0.55$1.88

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue (TTM)

$0.00

Net Income (TTM)

-$50M

▲ +20.7% YoY

Op. Margin

–

ROIC

-115.92%

▲ +55.6pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$19M

▲ +13.1% YoY

Op. Cash Flow (TTM)

-$19M

▲ +13.1% YoY

Net Debt

-$41M

Net Cash Position

Cash & Equiv.

$41M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with RNTX

CompareIntrinsic value

ANVSAnnovis Bio, Inc.

$1.21+11.01%10

EVFMEvofem Biosciences Inc.

$0.01+0.00%15

HCWBHCW Biologics Inc.

$1.08-6.09%15

CUECue Biopharma, Inc.

$19.84-4.89%40

BYSIBeyondSpring Inc.

$0.68+9.34%10

CAPRCapricor Therapeutics Inc.

$8.92+8.25%10

MGNXMacrogenics Inc.

$2.31-0.86%36

VREOFVireo Growth Inc.

$7.29-2.15%30

Rein Therapeutics (RNTX) in three numbers

Quality score: 10/100; Best check: net debt, -$41M. Weakest: return on capital, -115.9%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -0.38; Negative: a loss over the last twelve months. Price to free cash flow -3.02.; Financials

Questions about Rein Therapeutics

Is Rein Therapeutics a high-quality business?

Rein Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$41M, and its weakest is return on capital at -115.9%. The Quality tab shows every check against its target.

Does Rein Therapeutics (RNTX) pay a dividend?

No. Rein Therapeutics (RNTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in RNTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RNTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.